Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting
Authors:
- Åsa K WallinÅWÅsa K Wallin
- Lennart MinthonLMLennart Minthon
Open Access
- 1 September 2011
- journal article
- research article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 7 (1) , 565-576
Abstract
Background: In the absence of long-term, placebo-controlled studies of cholinesterase inhibitors in Alzheimer's disease (AD), analysis of the results of open-label trials becomes crucial. This study aimed to explore the three-year effects of galantamine treatment, as well as subgroups of response and adherence to treatment. Methods: Two hundred and eighty patients with a clinical diagnosis of AD were included in the prospective, open-label, multicenter Swedish Alzheimer Treatment Study, and received galantamine treatment. Efficacy measures included cognitive tests, ie, the Mini-Mental State Examination (MMSE) and Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-cog), functional rating (Instrumental Activities of Daily Living Scale [IADL]), and global rating. Assessments were carried out before treatment and every six months for a period of three years. K-means cluster analysis was used to identify response subgroups. Results: After three years of treatment, the mean change from baseline was 2.6 points in MMSE and 5.6 points in ADAS-cog scores. Globally, half of the patients improved or remained unchanged for two years. Cluster analysis identified two response clusters. Cluster 1 included patients with low ability in ADAS-cog and IADL scores at baseline. Even though the patients in cluster 1 were older and less educated, they responded better at six months compared with patients in cluster 2. Cluster 2 included patients with better ADAS-cog and IADL scores at baseline. Patients in cluster 2 had a higher frequency of the APOE ε4 allele, a slower pretreatment progression rate, and remained in the study longer than those in cluster 1. Three-year completers (n = 129, 46%) received higher doses of galantamine compared with dropouts. Conclusion: AD patients who received long-term galantamine treatment were cognitively and globally stabilized. Subgroup response analysis identified a better short-term response in older patients with lower cognitive and functional abilities at baseline, a faster pretreatment progression rate, and a lower incidence of the APOE ε4 allele. The galantamine dose was higher in the population of completers.Keywords
This publication has 55 references indexed in Scilit:
- Discontinuation of Cholinesterase Inhibitor Treatment and Determinants thereof in the NetherlandsDrugs & Aging, 2010
- Predicting progression of Alzheimer's diseaseAlzheimer's Research & Therapy, 2010
- Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled TrialJAMA, 2009
- Ageing populations: the challenges aheadThe Lancet, 2009
- Persistence with Cholinesterase Inhibitor Therapy for DementiaDrugs & Aging, 2009
- The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trialBMC Neurology, 2007
- Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChRActa Neurologica Scandinavica, 2000
- Worldwide Prevalence and Incidence of DementiaDrugs & Aging, 1999
- Clinical Global Impression of Change Clinical Global Impressions in Alzheimer’s Clinical TrialsInternational Psychogeriatrics, 1996
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984